Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 9/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 8/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 6/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 6/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.98 |
| ▸ | APP | P05067 | 5/20 | 0.86 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.86 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.86 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.86 |
| ▸ | HTR1A | P08908 | 1/20 | 0.86 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.86 |
| ▸ | DRD2 | P14416 | 1/20 | 0.86 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.86 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.86 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.86 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.86 |
| ▸ | HTR2B | P41595 | 1/20 | 0.86 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isoquine SCHEMBL31672531 | 0.99 | CYP3A4 (1.00) | CYP2D6CYP1A2CYP2C8CYP2C19KCNH2 | |
| Amodiaquine SCHEMBL29425350 | 0.93 | CYP2D6 (1.00) | CYP2D6CYP1A2CYP2C8CYP2C19KCNH2 | |
| Amodiaquine SCHEMBL29441086 | 0.93 | CYP2D6 (1.00) | CYP2D6CYP1A2CYP2C8CYP2C19KCNH2 | |
| Amodiaquine SCHEMBL44152 | 0.93 | CYP2D6 (1.00) | CYP2D6CYP1A2CYP2C8CYP2C19KCNH2 | |
| Amodiaquine SCHEMBL29430175 | 0.92 | CYP2D6 (1.00) | CYP2D6CYP1A2CYP2C8CYP2C19KCNH2 | |
| Amodiaquine SCHEMBL317888 | 0.92 | CYP2D6 (1.00) | CYP2D6CYP1A2CYP2C8CYP2C19KCNH2 | |
| Amodiaquine SCHEMBL29788983 | 0.92 | CYP2D6 (1.00) | CYP2D6CYP1A2CYP2C8CYP2C19KCNH2 | |
| Amodiaquine SCHEMBL12094969 | 0.92 | CYP2D6 (1.00) | CYP2D6CYP1A2CYP2C8CYP2C19KCNH2 | |
| Amodiaquine SCHEMBL1491204 | 0.91 | CYP2D6 (1.00) | CYP2D6CYP1A2CYP2C8CYP2C19KCNH2 | |
| Amodiaquine SCHEMBL284774 | 0.91 | CYP2D6 (0.96) | CYP2D6CYP1A2CYP2C8CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| EP-4698662-A2 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | AskBio Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| WO-2025085979-A1 | PAN-SPECIFIC MALARIA BINDING POLYPEPTIDES | ADALTA LIMITED (AU) | 2025-05-01 | — | — | WO | disclosed |
| WO-2024220449-A9 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | AskBio Inc. (US) | 2025-04-03 | — | — | WO | disclosed |
| WO-2024220449-A2 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | ASKLEPIOS BIOPHARMACEUTICAL, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-12049494-B2 | Compositions and methods for detection of malaria biomarkers | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-07-30 | — | — | US | disclosed |
| WO-2024016639-A1 | ANTI-VIRAL-INFECTION COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 华创合成制药股份有限公司 | 2024-01-25 | — | — | WO | disclosed |
| CN-111217811-B | Fused tricyclic compounds and application thereof in medicines | 广东东阳光药业股份有限公司 | 2024-01-16 | — | — | CN | disclosed |
| WO-2024008048-A1 | NOVEL PYRIMIDINE OR TRIAZINE-SUBSTITUTED PYRIDOHETEROCYCLIC COMPOUND | 杭州德睿智药科技有限公司 | 2024-01-11 | — | — | WO | disclosed |
| CN-109432440-B | Praziquantel hydroxypropyl cyclodextrin inclusion compound and preparation method and application thereof | 佛山科学技术学院 | 2022-04-26 | — | — | CN | disclosed |
| WO-2019173482-A1 | 4-AMINOQUINOLINE COMPOUNDS FOR THE TREATMENT OF ANGIOGENESIS | Sanford Burnham Prebys Medical Discovery Institute (US) | 2019-09-12 | — | — | WO | disclosed |
| US-20090298868-A1 | QUINOLINE COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF | ORLOW SETH J | 2009-12-03 | — | — | US | disclosed |
| WO-2009064492-A1 | QUINOLINE COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF | NEW YORK UNIVERSITY SCHOOL OF MEDICINE (US) | 2009-05-22 | — | — | WO | disclosed |
| US-7488721-B2 | Real time methylumbelliferone-based assay | MCMASTER UNIVERSITY (CA) | 2009-02-10 | — | — | US | disclosed |
| US-7488721-B2 | Real time methylumbelliferone-based assay | MCMASTER UNIVERSITY (CA) | 2009-02-10 | — | — | US | disclosed |
| US-7132431-B2 | Anti-malarial compounds | THE UNIVERSITY OF LIVERPOOL (GB) | 2006-11-07 | — | — | US | disclosed |
| US-20040152729-A1 | Anti-malarial compounds | THE LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2004-08-05 | — | — | US | disclosed |
| EP-1368321-A1 | ANTI-MALARIAL COMPOUNDS | THE UNIVERSITY OF LIVERPOOL (GB) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002072554-A1 | ANTI-MALARIAL COMPOUNDS | THE UNIVERSITY OF LIVERPOOL (GB) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298868-A1 | QUINOLINE COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF | TYR, MITF, MC1R | CYP2D6 473/4885CYP1A2 172/4885CYP2C8 1197/4885 |
| US-20040152729-A1 | Anti-malarial compounds | HMBS, MEP1A, QDPR | CYP2D6 367/4885CYP1A2 277/4885CYP2C8 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.